R2 $86 Mil. Offering Would Fund LungCheck CAD Software Development
This article was originally published in The Gray Sheet
Executive Summary
R2 Technologies' proposed initial public offering will fund development of the LungCheck computer-aided detection (CAD) system for screening abnormalities in chest computerized tomography (CT) scans, and shore up its current mammography CAD business
You may also be interested in...
Financings In Brief
R2 Technologies cancels IPO: Poor economic conditions are cited as the grounds for withdrawing a proposed $86 mil. initial public offering. The Los Altos, Calif.-based firm planned to use proceeds from the IPO to fund development of its LungCheck computer-aided detection (CAD) system for screening abnormalities in chest computed tomography scans and expanded marketing initiatives for its ImageChecker mammography CAD system, approved in 1998. The IPO prospectus was filed with the Securities & Exchange Commission in December 2001 (1"The Gray Sheet" Jan. 7, 2002, p. 18)...
Financings In Brief
R2 Technologies cancels IPO: Poor economic conditions are cited as the grounds for withdrawing a proposed $86 mil. initial public offering. The Los Altos, Calif.-based firm planned to use proceeds from the IPO to fund development of its LungCheck computer-aided detection (CAD) system for screening abnormalities in chest computed tomography scans and expanded marketing initiatives for its ImageChecker mammography CAD system, approved in 1998. The IPO prospectus was filed with the Securities & Exchange Commission in December 2001 (1"The Gray Sheet" Jan. 7, 2002, p. 18)...
Fischer, R2 PMA Supplements Aimed At SenoScan/ImageChecker Combo
Fischer Imaging and R2 Technology are preparing separate PMA supplements to allow marketing of SenoScan full field digital mammography systems integrating R2's ImageChecker computer aided detection (CAD) technology